Metabolic & Endocrine
Type 1 Diabetes (T1D)
3
Pipeline Programs↗
10
Active Trials↗
5
Companies Involved↗
Type 1 Diabetes (T1D) is an early-stage landscape with 3 programs across 5 companies. The most active players are Johnson & Johnson, Amylyx Pharmaceuticals Inc., Eli Lilly. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 31
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Monoclonal antibody150%
Modality classified for 50% of 4 pipeline programs.
Analysis
Trial Status
11
clinical trials
Recruiting6 · 55%
Not yet recruiting4 · 36%
Completed1 · 9%
Clinical Trials
Trial Activity
11 trials
Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by Prediction (INSIGHT)
Recruiting·—·Preclinical·NCT07507708·20 enrolled
Adaptive Platform Trial to Delay Progression From Normoglycemia to Dysglycemia in Presymptomatic Type 1 Diabetes: Golimumab Substudy
Not yet recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT07683026·255 enrolled
Dietary Approaches for the Management of Overweight and Obesity in Type 1 Diabetes: The D1ANA Study
Not yet recruiting·FFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud·Preclinical·NCT07667504·75 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)